余睿女士自 2023 年 12 月起擔(dān)任本公司董事，并自 2024 年 6 月起兼任首席財(cái)務(wù)官。此外，余睿女士自 2021 年 5 月起擔(dān)任海松資本醫(yī)療保健業(yè)務(wù)合伙人，負(fù)責(zé)制定醫(yī)療保健領(lǐng)域的整體投資策略。在此之前，余睿女士曾于 2014 年至 2021 年任職于華興資本（China Renaissance），先后擔(dān)任 CR Life Star Fund 合伙人及華興資本醫(yī)療與生命科技組董事總經(jīng)理。在此期間，她主導(dǎo)了近 30 個(gè)知名公司的私募融資和股權(quán)投資項(xiàng)目，其中多個(gè)項(xiàng)目成功上市，總交易額超過(guò) 30 億美元。此前，她還曾在美國(guó)格理集團(tuán)擔(dān)任副總裁、研究部負(fù)責(zé)人兼中國(guó)醫(yī)療保健業(yè)務(wù)負(fù)責(zé)人，積累了深厚的行業(yè)資源。

余睿女士在美國(guó)工作十余年，擁有多元化的職業(yè)背景。她曾擔(dān)任德意志銀行（Deutsche Bank）等知名投行的美國(guó)醫(yī)療行業(yè)股票分析師，專注于美國(guó)生命科技公司的股票研究，并曾在全球頂尖藥企 —— 美國(guó)基因泰克公司（Genentech）研發(fā)部任職五年，擔(dān)任醫(yī)藥研究員。

余睿女士依次擁有芝加哥大學(xué)布斯商學(xué)院 MBA 學(xué)位、密蘇里大學(xué)藥理學(xué)碩士學(xué)位及廣東藥科大學(xué)藥學(xué)學(xué)士學(xué)位。

Director and Chief Financial Officer

Ms. Rachel Yu has served as our director since December 2023 and Chief Financial Officer since June 2024. Ms. Yu is a partner at Oceanpine Capital’s healthcare practice since May 2021, where she is responsible for formulating the overall investment strategies in the healthcare sector and taking day-to-day principal leadership responsibility in financial and operational management of financial team, investment team and portfolio companies. 

Prior to that, she was a partner at China Renaissance Group, where she worked from 2014 to 2021 and took the principal responsibility in deal sourcing, and conducting due diligence on investment targets, including financial and operational data, financial models and valuation and compliance. From 2012 to 2014, Ms. Yu served as vice president/head of China healthcare research at Gerson Lehman Group. Prior to that, Ms. Yu worked as an equity analyst at Maxim Group, Rodman & Renshaw, and Deutsche Bank Securities. 

Ms. Yu received her MBA from the University of Chicago Booth School of Business (2008-2010), her MSc in Pharmacology from The University of Missouri School of Medicine (2000-2002), and her BSc in Pharmacy from Guangdong Pharmaceutical University (1995-1999).